Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Cell Rep Med ; 1(7): 100101, 2020 10 20.
Article in English | MEDLINE | ID: mdl-33103128

ABSTRACT

Tumor-educated platelets (TEPs) are potential biomarkers for cancer diagnostics. We employ TEP-derived RNA panels, determined by swarm intelligence, to detect and monitor glioblastoma. We assessed specificity by comparing the spliced RNA profile of TEPs from glioblastoma patients with multiple sclerosis and brain metastasis patients (validation series, n = 157; accuracy, 80%; AUC, 0.81 [95% CI, 0.74-0.89; p < 0.001]). Second, analysis of patients with glioblastoma versus asymptomatic healthy controls in an independent validation series (n = 347) provided a detection accuracy of 95% and AUC of 0.97 (95% CI, 0.95-0.99; p < 0.001). Finally, we developed the digitalSWARM algorithm to improve monitoring of glioblastoma progression and demonstrate that the TEP tumor scores of individual glioblastoma patients represent tumor behavior and could be used to distinguish false positive progression from true progression (validation series, n = 20; accuracy, 85%; AUC, 0.86 [95% CI, 0.70-1.00; p < 0.012]). In conclusion, TEPs have potential as a minimally invasive biosource for blood-based diagnostics and monitoring of glioblastoma patients.


Subject(s)
Blood Platelets/metabolism , Brain Neoplasms/diagnosis , Glioblastoma/diagnosis , Monitoring, Physiologic/methods , Multiple Sclerosis/diagnosis , RNA, Neoplasm/genetics , Adult , Aged , Aged, 80 and over , Algorithms , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Blood Platelets/pathology , Brain Neoplasms/genetics , Brain Neoplasms/mortality , Brain Neoplasms/surgery , Case-Control Studies , Disease Progression , Glioblastoma/genetics , Glioblastoma/mortality , Glioblastoma/surgery , Humans , Middle Aged , Multiple Sclerosis/genetics , Multiple Sclerosis/pathology , Neoplasm Metastasis , RNA Splicing , RNA, Neoplasm/metabolism , ROC Curve , Survival Analysis , Tumor Microenvironment/genetics
2.
Clin Cancer Res ; 24(6): 1337-1343, 2018 03 15.
Article in English | MEDLINE | ID: mdl-29284707

ABSTRACT

Purpose: We sought to investigate the clinical response to MET inhibition in patients diagnosed with structural MET alterations and to characterize their functional relevance in cellular models.Experimental Design: Patients were selected for treatment with crizotinib upon results of hybrid capture-based next-generation sequencing. To confirm the clinical observations, we analyzed cellular models that express these MET kinase alterations.Results: Three individual patients were identified to harbor alterations within the MET receptor. Two patients showed genomic rearrangements, leading to a gene fusion of KIF5B or STARD3NL and MET One patient diagnosed with an EML4-ALK rearrangement developed a MET kinase domain duplication as a resistance mechanism to ceritinib. All 3 patients showed a partial response to crizotinib that effectively inhibits MET and ALK among other kinases. The results were further confirmed using orthogonal cellular models.Conclusions: Crizotinib leads to a clinical response in patients with MET rearrangements. Our functional analyses together with the clinical data suggest that these structural alterations may represent actionable targets in lung cancer patients. Clin Cancer Res; 24(6); 1337-43. ©2017 AACR.


Subject(s)
Adenocarcinoma of Lung/genetics , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins c-met/antagonists & inhibitors , Proto-Oncogene Proteins c-met/genetics , Adenocarcinoma of Lung/diagnosis , Adenocarcinoma of Lung/drug therapy , Adenocarcinoma of Lung/metabolism , Adult , Anaplastic Lymphoma Kinase/antagonists & inhibitors , Crizotinib/pharmacology , Crizotinib/therapeutic use , Female , Gene Duplication , Gene Rearrangement , Humans , Immunohistochemistry , Male , Middle Aged , Molecular Targeted Therapy , Neoplasm Staging , Oncogene Proteins, Fusion/chemistry , Oncogene Proteins, Fusion/genetics , Oncogene Proteins, Fusion/metabolism , Protein Binding , Protein Interaction Domains and Motifs , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins c-met/chemistry , Tomography, X-Ray Computed
3.
Oncotarget ; 8(36): 60447-60452, 2017 09 01.
Article in English | MEDLINE | ID: mdl-28947983

ABSTRACT

Historically, the diagnosis of diffuse intrinsic pontine glioma (DIPG) was based on typical imaging findings and clinical characteristics instead of pathology. However, the discovery of mutations in histone H3 variants, and the availability of tumor material for molecular analysis, has led to a paradigm shift in DIPG research and clinical practice. Using data from whole-brain autopsies in a series of nine DIPG patients with known histone mutational status, we here aim to review histopathological characteristics with special focus on intratumoral heterogeneity (ITH) and histone 3 K27 trimethylation (H3 K27me3). All DIPGs showed marked histologic ITH, with 56% even showing focal areas resembling a WHO grade I phenotype. As expected, H3 K27me3 immunoreactivity was lost in the tumors that were H3 K27M-mutated (seven patients; 67% H3.3, 11% H3.1). Strikingly, the H3K27 wildtype tumors (two patients; 22%) also contained H3 K27me3-immunonegative areas. Our study underscores the importance of the choice of the biopsy site, as ITH in DIPGs could theoretically lead to erroneous histological diagnoses with small biopsies. New in this respect is our finding that a substantial number of otherwise typical DIPGs has areas resembling WHO grade I tumors (esp. pilocytic astrocytoma, subependymoma). Furthermore, our study shows that negative H3 K27me3 immunohistochemistry in a DIPG does not imply a H3 K27-mutant tumor.

4.
Cancer Cell ; 32(2): 238-252.e9, 2017 08 14.
Article in English | MEDLINE | ID: mdl-28810146

ABSTRACT

Blood-based liquid biopsies, including tumor-educated blood platelets (TEPs), have emerged as promising biomarker sources for non-invasive detection of cancer. Here we demonstrate that particle-swarm optimization (PSO)-enhanced algorithms enable efficient selection of RNA biomarker panels from platelet RNA-sequencing libraries (n = 779). This resulted in accurate TEP-based detection of early- and late-stage non-small-cell lung cancer (n = 518 late-stage validation cohort, accuracy, 88%; AUC, 0.94; 95% CI, 0.92-0.96; p < 0.001; n = 106 early-stage validation cohort, accuracy, 81%; AUC, 0.89; 95% CI, 0.83-0.95; p < 0.001), independent of age of the individuals, smoking habits, whole-blood storage time, and various inflammatory conditions. PSO enabled selection of gene panels to diagnose cancer from TEPs, suggesting that swarm intelligence may also benefit the optimization of diagnostics readout of other liquid biopsy biosources.


Subject(s)
Algorithms , Artificial Intelligence , Blood Platelets/physiology , Carcinoma, Non-Small-Cell Lung/diagnosis , Diagnosis, Computer-Assisted/methods , Lung Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor , Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Non-Small-Cell Lung/genetics , Cohort Studies , Female , Gene Expression Profiling , High-Throughput Nucleotide Sequencing , Humans , Inflammation/blood , Inflammation/diagnosis , Inflammation/genetics , Lung Neoplasms/blood , Lung Neoplasms/genetics , Male , Middle Aged , Support Vector Machine
5.
Oncotarget ; 7(1): 1066-75, 2016 Jan 05.
Article in English | MEDLINE | ID: mdl-26544515

ABSTRACT

PURPOSE: Non-small-cell lung cancers harboring EML4-ALK rearrangements are sensitive to crizotinib. However, despite initial response, most patients will eventually relapse, and monitoring EML4-ALK rearrangements over the course of treatment may help identify these patients. However, challenges associated with serial tumor biopsies have highlighted the need for blood-based assays for the monitoring of biomarkers. Platelets can sequester RNA released by tumor cells and are thus an attractive source for the non-invasive assessment of biomarkers. METHODS: EML4-ALK rearrangements were analyzed by RT-PCR in platelets and plasma isolated from blood obtained from 77 patients with non-small-cell lung cancer, 38 of whom had EML4-ALK-rearranged tumors. In a subset of 29 patients with EML4-ALK-rearranged tumors who were treated with crizotinib, EML4-ALK rearrangements in platelets were correlated with progression-free and overall survival. RESULTS: RT-PCR demonstrated 65% sensitivity and 100% specificity for the detection of EML4-ALK rearrangements in platelets. In the subset of 29 patients treated with crizotinib, progression-free survival was 3.7 months for patients with EML4-ALK+ platelets and 16 months for those with EML4-ALK- platelets (hazard ratio, 3.5; P = 0.02). Monitoring of EML4-ALK rearrangements in the platelets of one patient over a period of 30 months revealed crizotinib resistance two months prior to radiographic disease progression. CONCLUSIONS: Platelets are a valuable source for the non-invasive detection of EML4-ALK rearrangements and may prove useful for predicting and monitoring outcome to crizotinib, thereby improving clinical decisions based on radiographic imaging alone.


Subject(s)
Blood Platelets/metabolism , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Oncogene Proteins, Fusion/genetics , Pyrazoles/therapeutic use , Pyridines/therapeutic use , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Non-Small-Cell Lung/genetics , Crizotinib , Drug Monitoring/methods , Female , Humans , In Situ Hybridization, Fluorescence , Kaplan-Meier Estimate , Lung Neoplasms/blood , Lung Neoplasms/genetics , Male , Middle Aged , Oncogene Proteins, Fusion/blood , Outcome Assessment, Health Care/methods , Outcome Assessment, Health Care/statistics & numerical data , Prognosis , Proportional Hazards Models , Protein Kinase Inhibitors/therapeutic use , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction
6.
Cancer Cell ; 28(5): 666-676, 2015 Nov 09.
Article in English | MEDLINE | ID: mdl-26525104

ABSTRACT

Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic and local responses to tumor growth, thereby altering their RNA profile. We determined the diagnostic potential of TEPs by mRNA sequencing of 283 platelet samples. We distinguished 228 patients with localized and metastasized tumors from 55 healthy individuals with 96% accuracy. Across six different tumor types, the location of the primary tumor was correctly identified with 71% accuracy. Also, MET or HER2-positive, and mutant KRAS, EGFR, or PIK3CA tumors were accurately distinguished using surrogate TEP mRNA profiles. Our results indicate that blood platelets provide a valuable platform for pan-cancer, multiclass cancer, and companion diagnostics, possibly enabling clinical advances in blood-based "liquid biopsies".


Subject(s)
Biomarkers, Tumor/genetics , Blood Platelets/metabolism , Neoplasms/genetics , Signal Transduction/genetics , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , Class I Phosphatidylinositol 3-Kinases , ErbB Receptors/genetics , Female , Gene Expression Profiling/methods , Gene Ontology , Humans , Male , Middle Aged , Mutation , Neoplasms/blood , Neoplasms/diagnosis , Pathology, Molecular/methods , Phosphatidylinositol 3-Kinases/genetics , Proto-Oncogene Proteins c-met/genetics , Proto-Oncogene Proteins p21(ras)/genetics , Receptor, ErbB-2/genetics , Reproducibility of Results , Sensitivity and Specificity , Sequence Analysis, RNA/methods , Support Vector Machine , Young Adult
7.
J Neurosci Methods ; 238: 88-94, 2014 Dec 30.
Article in English | MEDLINE | ID: mdl-25263805

ABSTRACT

BACKGROUND: Systemic delivery of therapeutic agents remains ineffective against diffuse intrinsic pontine glioma (DIPG), possibly due to an intact blood-brain-barrier (BBB) and to dose-limiting toxicity of systemic chemotherapeutic agents. Convection-enhanced delivery (CED) into the brainstem may provide an effective local delivery alternative for DIPG patients. NEW METHOD: The aim of this study is to develop a method to perform CED into the murine brainstem and to test this method using the chemotherapeutic agent carmustine (BiCNU). To this end, a newly designed murine CED catheter was tested in vitro and in vivo. After determination of safety and distribution, mice bearing VUMC-DIPG-3 and E98FM-DIPG brainstem tumors were treated with carmustine dissolved in DW 5% or carmustine dissolved in 10% ethanol. RESULTS: Our results show that CED into the murine brainstem is feasible and well tolerated by mice with and without brainstem tumors. CED of carmustine dissolved in 5% DW increased median survival of mice with VUMC-DIPG-3 and E98FM-DIPG tumors with 35% and 25% respectively. Dissolving carmustine in 10% ethanol further improved survival to 45% in mice with E98FM-DIPG tumors. COMPARISON WITH EXISTING METHODS: Since genetically engineered and primary DIPG models are currently only available in mice, murine CED studies have clear advantages over CED studies in other animals. CONCLUSION: CED in the murine brainstem can be performed safely, is well tolerated and can be used to study efficacy of chemotherapeutic agents orthotopically. These results set the foundation for more CED studies in murine DIPG models.


Subject(s)
Antineoplastic Agents/administration & dosage , Brain Stem/drug effects , Carmustine/administration & dosage , Catheters , Convection , Drug Delivery Systems/methods , Animals , Brain Stem/pathology , Brain Stem Neoplasms/drug therapy , Brain Stem Neoplasms/pathology , Brain Stem Neoplasms/physiopathology , Equipment Design , Ethanol/chemistry , Feasibility Studies , Glioma/drug therapy , Glioma/pathology , Glioma/physiopathology , Glucose/chemistry , Humans , Kaplan-Meier Estimate , Mice, Inbred BALB C , Mice, Nude , Mice, Transgenic , Neoplasm Transplantation , Solvents/chemistry , Treatment Outcome
9.
Acta Neuropathol ; 127(6): 897-909, 2014.
Article in English | MEDLINE | ID: mdl-24777482

ABSTRACT

Diffuse intrinsic pontine glioma (DIPG), with a median survival of only 9 months, is the leading cause of pediatric brain cancer mortality. Dearth of tumor tissue for research has limited progress in this disease until recently. New experimental models for DIPG research are now emerging. To develop preclinical models of DIPG, two different methods were adopted: cells obtained at autopsy (1) were directly xenografted orthotopically into the pons of immunodeficient mice without an intervening cell culture step or (2) were first cultured in vitro and, upon successful expansion, injected in vivo. Both strategies resulted in pontine tumors histopathologically similar to the original human DIPG tumors. However, following the direct transplantation method all tumors proved to be composed of murine and not of human cells. This is in contrast to the indirect method that included initial in vitro culture and resulted in xenografts comprising human cells. Of note, direct injection of cells obtained postmortem from the pons and frontal lobe of human brains not affected by cancer did not give rise to neoplasms. The murine pontine tumors exhibited an immunophenotype similar to human DIPG, but were also positive for microglia/macrophage markers, such as CD45, CD68 and CD11b. Serial orthotopic injection of these murine cells results in lethal tumors in recipient mice. Direct injection of human DIPG cells in vivo can give rise to malignant murine tumors. This represents an important caveat for xenotransplantation models of DIPG. In contrast, an initial in vitro culture step can allow establishment of human orthotopic xenografts. The mechanism underlying this phenomenon observed with direct xenotransplantation remains an open question.


Subject(s)
Brain Stem Neoplasms , Disease Models, Animal , Glioma , Neoplasm Transplantation/methods , Animals , Antigens, CD/metabolism , Antigens, Differentiation, Myelomonocytic/metabolism , Brain Stem Neoplasms/genetics , Brain Stem Neoplasms/pathology , Brain Stem Neoplasms/physiopathology , CD11b Antigen/metabolism , Cell Culture Techniques , Child , Female , Frontal Lobe/pathology , Frontal Lobe/physiopathology , Frontal Lobe/transplantation , Glioma/genetics , Glioma/pathology , Glioma/physiopathology , Humans , Infant , Leukocyte Common Antigens/metabolism , Male , Mice, Nude , Mice, SCID , Mice, Transgenic , Pons/pathology , Pons/physiopathology , Pons/transplantation , Young Adult
10.
Mol Cancer Ther ; 12(2): 141-50, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23270927

ABSTRACT

Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric disease. Thus far, no therapeutic agent has proven beneficial in the treatment of this malignancy. Therefore, conventional DNA-damaging radiotherapy remains the standard treatment, providing transient neurologic improvement without improving the probability of overall survival. During radiotherapy, WEE1 kinase controls the G(2) cell-cycle checkpoint, allowing for repair of irradiation (IR)-induced DNA damage. Here, we show that WEE1 kinase is one of the highest overexpressed kinases in primary DIPG tissues compared with matching non-neoplastic brain tissues. Inhibition of WEE1 by MK-1775 treatment of DIPG cells inhibited the IR-induced WEE1-mediated phosphorylation of CDC2, resulting in reduced G(2)-M arrest and decreased cell viability. Finally, we show that MK-1775 enhances the radiation response of E98-Fluc-mCherry DIPG mouse xenografts. Altogether, these results show that inhibition of WEE1 kinase in conjunction with radiotherapy holds potential as a therapeutic approach for the treatment of DIPG.


Subject(s)
Brain Stem Neoplasms/drug therapy , Brain Stem Neoplasms/radiotherapy , Cell Cycle Proteins/antagonists & inhibitors , Glioma/drug therapy , Glioma/radiotherapy , Nuclear Proteins/antagonists & inhibitors , Protein-Tyrosine Kinases/antagonists & inhibitors , Animals , Brain Stem Neoplasms/enzymology , Brain Stem Neoplasms/pathology , Combined Modality Therapy , Female , Glioma/enzymology , Glioma/pathology , Humans , Immunohistochemistry , Mice , Mice, Nude , Phosphorylation , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Pyrimidinones , Radiation-Sensitizing Agents/pharmacology , Random Allocation , Xenograft Model Antitumor Assays
11.
J Virol ; 82(20): 10312-7, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18667517

ABSTRACT

Coronaviruses are positive-strand RNA viruses of extraordinary genetic complexity and diversity. In addition to a common set of genes for replicase and structural proteins, each coronavirus may carry multiple group-specific genes apparently acquired through relatively recent heterologous recombination events. Here we describe an accessory gene, ORF3, unique to canine coronavirus type I (CCoV-I) and characterize its product, glycoprotein gp3. Whereas ORF3 is conserved in CCoV-I, only remnants remain in CCoV-II and CCoV-II-derived porcine and feline coronaviruses. Our findings provide insight into the evolutionary history of coronavirus group 1a and into the dynamics of gain and loss of accessory genes.


Subject(s)
Coronavirus, Canine/genetics , Coronavirus, Canine/metabolism , Glycoproteins/metabolism , Viral Envelope Proteins/metabolism , Amino Acid Sequence , Animals , Cats , Cluster Analysis , Coronavirus Infections/metabolism , Coronavirus, Canine/classification , Dogs , Glycoproteins/genetics , Molecular Sequence Data , Open Reading Frames , Phylogeny , Swine , Viral Envelope Proteins/genetics
12.
Microb Drug Resist ; 11(4): 383-6, 2005.
Article in English | MEDLINE | ID: mdl-16359199

ABSTRACT

Integrons in gentamicin- and cotrimoxazole-resistant Enterobacteriaceae from dogs and horses with clinical infections were analyzed by conserved segment PCR-RFLP. Five distinct integron types were found, most of which have previously been reported in Enterobacteriaceae isolated from humans and farm animals, indicating that resistance genes are exchanged between the reservoirs in humans, farm animals, and companion animals.


Subject(s)
Anti-Bacterial Agents/pharmacology , Dog Diseases/microbiology , Drug Resistance, Multiple, Bacterial , Enterobacteriaceae Infections/veterinary , Enterobacteriaceae/drug effects , Horse Diseases/microbiology , Integrons , Amino Acid Sequence/genetics , Animals , Anti-Bacterial Agents/therapeutic use , Dogs , Enterobacteriaceae/genetics , Enterobacteriaceae/isolation & purification , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/microbiology , Gentamicins/pharmacology , Gentamicins/therapeutic use , Horses , Microbial Sensitivity Tests/veterinary , Netherlands , Phenotype , Polymerase Chain Reaction , Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use
13.
J Virol ; 79(22): 14122-30, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16254347

ABSTRACT

In feline coronavirus (FCoV) pathogenesis, the ability to infect macrophages is an essential virulence factor. Whereas the low-virulence feline enteric coronavirus (FECV) isolates primarily replicate in the epithelial cells of the enteric tract, highly virulent feline infectious peritonitis virus (FIPV) isolates have acquired the ability to replicate efficiently in macrophages, which allows rapid dissemination of the virulent virus throughout the body. FIPV 79-1146 and FECV 79-1683 are two genetically closely related representatives of the two pathotypes. Whereas FECV 79-1683 causes at the most a mild enteritis in young kittens, FIPV 79-1146 almost invariably induces a lethal peritonitis. The virulence phenotypes correlate with the abilities of these viruses to infect and replicate in macrophages, a feature of FIPV 79-1146 but not of FECV 79-1683. To identify the genetic determinants of the FIPV 79-1146 macrophage tropism, we exchanged regions of its genome with the corresponding parts of FECV 79-1683, after which the ability of the FIPV/FECV hybrid viruses to infect macrophages was tested. Thus, we established that the FIPV spike protein is the determinant for efficient macrophage infection. Interestingly, this property mapped to the C-terminal domain of the protein, implying that the difference in infection efficiency between the two viruses is not determined at the level of receptor usage, which we confirmed by showing that infection by both viruses was equally blocked by antibodies directed against the feline aminopeptidase N receptor. The implications of these findings are discussed.


Subject(s)
Coronavirus, Feline/genetics , Coronavirus, Feline/pathogenicity , Feline Panleukopenia/pathology , Macrophages/physiology , Macrophages/virology , Membrane Glycoproteins/genetics , Viral Envelope Proteins/genetics , Amino Acid Sequence , Animals , Base Sequence , Bone Marrow Cells/pathology , Bone Marrow Cells/virology , Cats , Cell Culture Techniques , Conserved Sequence , Coronavirus, Feline/physiology , DNA Primers , Membrane Glycoproteins/chemistry , Molecular Sequence Data , Mutation , Plasmids , RNA, Viral/genetics , Sequence Alignment , Sequence Homology, Amino Acid , Spike Glycoprotein, Coronavirus , Viral Envelope Proteins/chemistry , Virus Replication
14.
Microb Drug Resist ; 11(1): 53-7, 2005.
Article in English | MEDLINE | ID: mdl-15770095

ABSTRACT

The presence and character of class 1 integrons in multidrug-resistant Escherichia coli from slaughter animals and meat was determined by integrase-specific PCR and conserved segment PCR-restriction fragment length polymorphism (RFLP). At least five different class 1 integron types were found and three types were shared between hospitalized patients, humans in the community, meat, and slaughter animals. Common integron types indicate that antibiotic resistance genes are exchanged via the food chain between different reservoirs of both human and animal origin.


Subject(s)
Drug Resistance, Multiple , Escherichia coli/genetics , Food Microbiology , Integrons/genetics , Animals , Cattle , Escherichia coli/enzymology , Escherichia coli/isolation & purification , Escherichia coli Infections/microbiology , Escherichia coli Infections/veterinary , Integrases/genetics , Netherlands , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length
SELECTION OF CITATIONS
SEARCH DETAIL
...